Physician profile
Robert Oberstein
NPI 1568404267
$516,042.68
in general payments reported to CMS, 2019-2025
47 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $49K · 2021: $51K · 2022: $85K · 2023: $92K · 2024: $75K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Food and Beverage: $14K · Travel and Lodging: $8,576 · Consulting Fee: $563 · Education: $77.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,075.63 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,000.01 |
| Food and Beverage | $13,577.94 |
| Travel and Lodging | $8,575.98 |
| Consulting Fee | $562.50 |
| Education | $77.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $307,540.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $77,603.34 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $62,217.85 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $31,975.27 | 2019-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,343.74 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $8,315.33 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $4,965.74 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $1,720.17 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $1,574.47 | 2019-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Amgen INC. | $1,306.06 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $396.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $366.65 | 2019-2023 | |
| Corcept Therapeutics | $364.99 | 2019-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $249.73 | 2023-2024 | Recorlev |
| Amneal Pharmaceuticals LLC | $214.77 | 2020-2025 | Unithroid |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.